Latest From Polyphor Ltd.
The Swiss firm is still examining options for the iv formulation of its novel antibiotic murepavadin even after it closed its two Phase III studies on safety concerns.
US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.
The Switzerland-headquartered group has suffered a setback as a couple of Phase III trials of its lead antibiotic were stopped temporarily after an unexpectedly high number of patients reported kidney injury.
News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Polyphor Ltd.
- Senior Management
Giacomo Di Nepi, CEO
Kalina Scott, CFO
Daniel Obrecht, PhD, CSO
Helmut Kessmann, PhD, Head, Bus. Dev.
Debra Barker, MD, CMO & Chief Dev. Officer
- Contact Info
Phone: (41) 61 567 16 00
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.